Background-Some aspects of prognosis are not reflected by cumulative survival estimates. These aspects include information on the time already survived by the patient and the patient's survival compared with the general population. Conditional survival (ie, conditional on having survived a certain period of time already) and relative conditional survival (ie, compared with the general population) do incorporate these aspects. We investigated these measures of prognosis in patients undergoing percutaneous coronary intervention. Methods and Results-We studied 17 903 consecutive patients undergoing percutaneous coronary intervention between 2000 and 2014. Cumulative survival was estimated for patients with ST-segment-elevation myocardial infarction (n=5996, 853 deaths), non-ST-segment-elevation myocardial infarction (n=5371, 901 deaths), and stable angina pectoris (n=6536, 965 deaths) in 4 age categories. One-year conditional and relative conditional survival up to 10 years postpercutaneous coronary intervention was calculated. The results demonstrated that 1-year cumulative survival for patients with ST-segment-elevation myocardial infarction aged ≥76 years was 83%. One-year conditional survival, conditional on surviving the first month, was 92% in this group, and relative conditional survival (relative to the general population) was 99%. In younger age categories and in patients with non-ST-segment-elevation myocardial infarction and stable angina pectoris , similar patterns were found albeit less pronounced. Five-year relative conditional rendered similar results. Conclusions-Relative conditional survival provides a comprehensive picture of patient prognosis, particularly for older patients with ST-segment-elevation myocardial infarction. Although, as expected, their cumulative survival is low, once they survive the first month after percutaneous coronary intervention, their prognosis is comparable to that of the general population. Therefore, relative conditional survival estimates provide an important, meaningful addition when discussing prognosis with patients. (Circ Cardiovasc Qual Outcomes. 2017;10:e003344.
P atients diagnosed with coronary artery disease often ask their treating cardiologist about their prognosis. 1 Currently, prognosis is usually presented in the form of percentage risk of fatal events up to a certain time point or, alternatively, cumulative probability of survival up to that time point (estimated by the Systematic Coronary Risk Evaluation [SCORE] for example). 2 To account for differences in patient characteristics, the probabilities are usually stratified on factors, such as age and sex. 2 
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However, cumulative survival probabilities fail to account for several aspects of prognosis. First, after surviving up to a certain point in time, a patient's prognosis may change. For example, after experiencing an acute myocardial infarction, adverse events are more likely to occur during the first month of follow-up. 3 Patients who survive this crucial period may have higher survival probabilities for the rest of the follow-up period. This issue may be addressed by calculating conditional survival (also known as landmark analysis). 4 Conditional survival estimates the survival probability from a certain time point onward, including only patients who were still alive at that time point. Therefore, it enables dynamic modeling of prognosis.
Second, cumulative survival includes death because of other reasons than the condition under investigation and may thus pose an overly pessimistic perspective on the effect of the disease on survival. This carries particular importance in elderly patients and during long-term follow-up. Calculating the survival probability of a patient relative to the survival probability in the general population (relative survival) may aid interpretation of cumulative survival. Relative survival probabilities are calculated by taking Relative Conditional Survival After PCI the ratio of the estimated survival in a certain patient cohort and the survival probability in the general population (expected survival) with the same age and sex. 5 Of note is that difficulties in interpretation, and overestimation of relative survival, may occur when a high proportion of deaths in the general population is because of the disease of interest. 6 Hinchliffe et al 6 have proposed an adjustment of the expected survival for such cases.
The 2 methods discussed above-conditional and relative survival-can be combined to calculate the relative conditional survival (ie, the relative survival probability after surviving a certain time period). Relative conditional survival can demonstrate to a patient at what moment in time his prognosis becomes similar to that of an otherwise comparable people who did not have the disease. 7 In the field of oncology, these types of survival probabilities are already being used. [7] [8] [9] In the cardiovascular field, use of these survival probabilities is less common. A few studies have examined conditional survival (or landmark analysis) and relative survival, but they examined these 2 entities separately. [10] [11] [12] [13] Moreover, these studies focused on patients with myocardial infarction; currently, no data are available on patients with stable coronary artery disease.
In this study, we estimated the relative conditional survival of 17 903 patients undergoing percutaneous coronary intervention (PCI) for ST-segment-elevation myocardial infarction (STEMI), non-ST-segment-elevation myocardial infarction (NSTEMI), or stable angina pectoris (SAP). Herewith, our study is the first to investigate whether incorporating information on a patient's survival up to a certain time point, as well as incorporating information on survival of the general population, provides additional insights into a patient's prognosis.
Methods

Study Population
A total of 17 903 consecutive patients undergoing PCI with stent placement between January 2000 and July 2014 at Erasmus Medical Center, Rotterdam, the Netherlands, were included in this study. Baseline data collection was performed prospectively and included age, sex, and indication for the index PCI (STEMI, NSTEMI, or SAP). The preferred stent type changed during the study period: bare metal stents were  used until April 2002, sirolimus-eluting stents between April 2002  and March 2003, paclitaxel-eluting stents between March 2003 and  March 2007, and everolimus-eluting stents between March 2007 and  July 2014. 14, 15 The preferred stent was almost exclusively used in all patients within these subsequent periods, except for (the small number of) patients who participated in trials comparing different stents. Patient management was in accordance with the applicable guidelines of the European Society of Cardiology, which changed over time. 16 The primary end point was all-cause mortality. Patients were actively followed up on this end point by periodically reviewing hospital medical records and municipal civil registries. The latest follow-up was performed in July 2015. Patients lost to follow-up were censored at the date they were last known to be alive at the municipal civil registries or at the hospitals.
Ethics
This was an observational study. For the purpose of this study, patients were not subjected to acts, neither was any mode of behavior imposed, otherwise than as part of their regular treatment. Therefore, according to Dutch law, written informed consent for a patient to be enrolled in this study was not required. This study was conducted according to the Privacy Policy of the Erasmus Medical Center and according to the Erasmus Medical Center regulations for the appropriate use of data in patient-oriented research.
Statistical Analysis
For the analyses, the patients were stratified on indication for PCI (STEMI, NSTEMI, and SAP) as well as age (22-55, 56-65, 66-75, and 76-95 years). Cumulative survival S ( ) was calculated using the Kaplan-Meier method, and SEs for survival were based on Greenwood formula. 5 Greenwood formula allows SEs to be calculated in a similar manner for cumulative survival, conditional survival, and relative conditional survival and was applied as such. Of note is that in previous papers, cumulative survival has often been termed observed survival to contrast it with relative survival. 5, 10 Survival probabilities with SEs ≤5% were considered reliable estimates as was done previously. 8 Conditional survival probabilities were calculated by taking the ratio of cumulative survival at a certain time point and cumulative survival at an earlier time point. Specifically, the x-year conditional survival, conditioned on having survived y years, was calculated by dividing the survival at y+x years by the survival at y years (Equation 1):
The difference between the survival at y and y+x years results in the x-year survival, conditional on surviving y years. 17 For example, the 1-year survival probability conditional on surviving 5 years is calculated as the ratio of the cumulative survival at 6 years divided by the cumulative survival at 5 years: ( ) ( )/ ( ) CS S S 15 5 1 5 | = + . To calculate relative survival, the expected survival is needed. One-year survival probabilities for the general population were retrieved from Statistics Netherlands (Centraal Bureau voor de Statistiek) on February 23, 2017 and were stratified on calendar year, age, and sex. 18 To account for the high incidence of coronary artery disease in the general population, the adjustment suggested by Hinchliffe et al 6 was applied here and adjusted expected survival was obtained ES
where ES are the survival probabilities directly obtained from Statistics Netherlands and α is the proportion of deaths because of the specific disease of interest. Approximations for α were made based on cause-specific deaths from Statistics Netherlands and disease prevalence estimates from literature. 19 This resulted in a specific α for each indication, year, age, and sex. Relative survival at a certain 10 using the Ederer II method. 5 Relative survival at y years is defined as:
WHAT IS KNOWN
We then combined both methods (conditional survival and relative survival) and calculated the relative survival at x conditional on y, which we call relative conditional survival, as follows:
For example, the 1-year relative survival probability conditional on 5 years is calculated as the ratio of the cumulative relative survival at 6 years divided by the cumulative relative survival at 5 years:
It should be noted that relative conditional probabilities may exceed 100%. Such situations may occur when the number of events is lower than expected compared with the general population during a certain follow-up period.
In this article, 1-year (relative) conditional survival probabilities were calculated-conditional on having already survived a certain period of time (CS y 1|
( ) and RCS y 1| ( )). However, in case a patient has already survived a substantial time period (ie, 5 or 10 years), it might not be clinically relevant to estimate only the short-term-that is, 1-year-survival probabilities. Therefore, the analyses were repeated calculating 5-year, instead of 1-year, survival probabilities (CS y 5|
( )
and RCS y 5|
( )).
To allow for correction for multiple variables at the same time, we subsequently applied regression models to our relative survival data. In such models, the hazard for a patient is split into the expected hazard and the excess hazard because of the disease of interest. Several methods are available, depending on the type of data and software available. In this study, we used the Poisson model. 20 For the interpretation of excess hazard to be valid, the assumption that the proportion of death because of the disease in the general population is negligible is of great importance. In this study, this was ensured by adjusting the expected survival. We included age, sex, follow-up time, indication for catheterization, and the interactions between the latter 2 variables in the model.
Continuous normal variables are presented as mean and SD, and non-normal variables are presented as median and interquartile range. Analyses were performed with SAS version 9.4. Relative survival was calculated with a publicly available SAS syntax and macro 20 that uses the Ederer II method. 5 The graphs were made with R version 3.3.2.
Results
Mean age was 63 years, and 72% were men. Indication for PCI was STEMI in 33%, NSTEMI in 30%, and SAP in 37% of the patients. Median survival time in months was 42 (interquartile range, 22-83 months; Table 1 ). Follow-up information was complete until July 31, 2015, for 98% of the patients. Figure 1 shows Kaplan-Meier curves with 95% confidence intervals for cumulative survival. Corresponding survival probabilities for certain time points during follow-up are given in Table 2 . For all 3 indications for PCI, clear differences were present in cumulative survival between the age groups. As expected, the oldest patients had the lowest survival probabilities, and the probabilities diverged during follow-up with patients aged 76 to 95 years showing the largest decrease (P<0.01 between all age groups at 10 years; Figure 1 ; Table 2 ).
In Table 3 , the 1-year conditional and 1-year relative conditional survival probabilities are shown together with the number of patients at the start of each interval and the number of deaths during that interval. Because of a limited number of patients aged 76 to 95 years at the end of the follow-up period, reliable estimates could not be calculated for all 1-year survival probabilities conditional on 9 years survival. Table I in the Data Supplement presents the expected survival estimates used to calculate relative survival. Figure 2 gives a graphical representation of these results. Because the first period of follow-up showed to be the most interesting, additional plots were inserted into Figure 2A , plotting the conditional survival in the first 6 months in more detail. Figure I in the Data Supplement depicts separate curves for observed and expected survival for patients with STEMI, on which the relative conditional survival estimates in Figure 2B are based. As expected, overall, when conditioned on surviving the first month ( CS 1 1 year| month ( ) ), 1-year conditional survival probabilities were higher compared with the 1-year survival probability at the start of follow-up (Table 3 ). This finding was most pronounced in the eldest patients with STEMI. Specifically, for these patients, the 1-year survival probability from the start of follow-up at the index event was 83% (95% confidence interval, 81%-86%). For patients from this category who survived the first month after the PCI, the 1-year conditional survival was 92% (90%-94%). When conditioned on surviving the first year, the 1-year conditional survival probability was even higher for the 2 oldest age groups in the patients with STEMI, with those aged 76 to 95 years having an estimated 1-year survival of 95% (93%-96%). For the younger patients, it was 99% (99%-99%). When conditioned on even Prior PCI, n (%) 1971 (11) 341 (6) 636 (12) 994 (15) Prior CABG, n (%) 1424 (8) 144 (2) 527 (10) 753 (12) CABG indicates coronary artery bypass grafting; IQR, interquartile range; MI, myocardial infarction; NSTEMI, non-ST-segment-elevation myocardial infarction; PCI, percutaneous coronary intervention; SAP, stable angina pectoris; and STEMI, ST-segment-elevation myocardial infarction.
longer survival (4 and 9 years), the 1-year conditional survival probabilities remained the same or were at most 3% lower. Higher 1-year survival is reflected by the initial sharp increase shown in Figure 2A . The increase was most prominent in the first month, as illustrated by the subplots in Figure 2 . Relative conditional survival was similar to conditional survival in the younger patients with STEMI. Conditional probabilities were already ≈100%, and relative conditional probabilities were only slightly higher, indicating that reporting relative survival is less useful when observed survival probabilities are already high. However, in the older age categories, relative conditional survival was markedly higher than conditional survival (Table 3; Figure 2B ). Patients with STEMI aged 76 to 95 years had a 1-year relative survival probability of 89% (87%-92%; opposed to 83% 1-year cumulative survival), and if they survived the first month, their 1-year relative conditional survival was 99% (97%-101%; 92% for conditional survival).
Similar results, albeit less outspoken, were present in the patients with NSTEMI and SAP. When conditioned on the first month of survival, 1-year conditional survival probabilities were slightly higher than the 1-year survival from the start of follow-up (Table 3 ; Figure 2A ). When conditioned on longer periods of survival (4 or 9 years), 1-year conditional survival probabilities decreased slightly. For example, patients with SAP aged 76 to 95 years showed a 1-year survival probability of 96% (94%-97%) conditional on 1 year of survival. This was 92% (89%-94%) conditioned on 4 years of survival and 88% (76%-95%) conditioned on 9 years. The 1-year relative conditional survival probabilities (Table 3 ; Figure 2B ) again shifted upward compared with the 1-year observed conditional survival. The decrease found in the 1-year conditional survival probabilities, conditioned on surviving 4 and 9 years, was not present in the 1-year relative conditional survival. Conditional on having survived the first months, the relative conditional survival probabilities remained ≥97% throughout follow-up.
When comparing the 3 indications for PCI, overall, patients with SAP had better prognosis than patients with NSTEMI, and patients with NSTEMI performed better than patients with STEMI. For cumulative survival, the difference was most prominent in the patients aged 76 to 95 years ( Figure 1 ; Table 2 ). In this age category, at 5 years of followup, cumulative survival of patients with SAP was 6% higher compared with patients with NSTEMI (P=0.008) and 10% higher compared with patients with STEMI (P<0.001). After conditioning on survival of the first month, the differences in prognosis between the patient groups were smaller, and the 1-year probabilities across the groups varied no more than 5% for the same age categories.
The 5-year survival probabilities can be found in Tables II  and III in the Data Supplement. Results remained essentially the same; however, the differences between conditional and relative conditional survival were more pronounced than in the 1-year survival estimates. The latter illustrates that in this PCI population, long-term (ie, 5 year) survival is also excellent when compared with the general population.
We stratified our main analyses on indication for PCI and age. However, sex may also have important effects on survival probability. One-and 5-year survival tables stratified on sex and age can be found in Tables IV through VI in the Data Supplement. Differences in cumulative survival between men and women were most prominent in patients aged 76 to 95 years; in the remaining age groups, all differences were no larger than 5%. Specifically, women aged 76 to 95 years showed higher cumulative survival (P<0.001 at 5 years). For the 1-year conditional and 1-year relative conditional survival probabilities, the differences were no larger than 3%, except for the eldest patients conditioned on 9-year follow-up. Here, the survival for men was 7% and 11% higher for conditional and relative conditional survival, respectively, although not statistically significant. In the table with the 5-year survival, older women displayed higher 5-year conditional survival probabilities than men until 5 years into follow-up. Conditioned on surviving 8 years, men showed higher 5-year conditional survival probabilities although all differences were not significant. Men seemed to perform better than women relative to the general population of their age and sex. These sex-specific survival estimates Relative Conditional Survival After PCI may in part have been confounded by sex differences in indication for intervention. In men, 35%, 29%, and 36% experienced STEMI, NSTEMI, and SAP, respectively. In women, these proportions were 30%, 33%, and 37%, respectively.
Because reliable estimates could not be obtained after simultaneous stratification on age, sex, and indication of intervention due to sample size limitations, a relative survival regression model was fitted, where the number of deaths in a time interval was assumed to have a Poisson distribution. 20 The variables included in the model were indication for catheterization, sex, age (per 1-year increase), and an interaction between indication and moment of assessment (before versus after 1 year of follow-up). This model resulted in relative excess risk (RER) estimates (ie, the difference between expected and observed hazard) for each of the 3 indications for the first year of follow-up compared with the remainder of the follow-up (Table 4 ). The RER of 6.98 (95% confidence interval, 4.95-9.85) for the patients with STEMI indicates that the excess risk of mortality (compared with the general population) is almost 7× higher in the first year after PCI than in the remainder of the follow-up for patients with STEMI (P<0.001), adjusted for age and sex. For patients with NSTEMI and SAP, the RER in the first year after PCI compared with the rest of the follow-up was smaller (2.76 [2.06-3.69] and 2.33 [1.53-3.56], respectively) but also highly significant. This coincides with the findings from the stratified analyses and illustrates that the first period after PCI (in the case of the model, the first year) is the most crucial and that this is most pronounced in patients with STEMI. In a post hoc analysis, the RER in the first month of follow-up was compared with the remainder of the follow-up, resulting in even larger and highly significant RER estimates (P<0.001). Furthermore, the model provided RER estimates for STEMI and NSTEMI compared with SAP after 1 year of follow-up. The results demonstrated that although no significant excess hazard for patients with STEMI compared with the patients with SAP is present within the time period 1 year after PCI and onward, an excess hazard was present for the patients with NSTEMI compared with the patients with SAP. The latter, with an RER estimate of 1.91 (1.32-2.76), indicates that even after the patients have stabilized, the excess risk of mortality for patients with NSTEMI remains twice as high as for the patients with SAP. The difference in excess risk between men and women (RER=1.38 [1.14-1.66], ie, 38% higher for women) coincides with the results found in the stratified analyses.
Discussion
In this study, we reported multiple measures of prognosis in 17 903 patients who underwent a PCI procedure for STEMI, NSTEMI, or SAP and were followed for up to 13 years post-PCI. We found that the 1-year cumulative survival probability for patients with STEMI aged 76 to 95 years was 83% (95% confidence interval, 81%-86%), but when conditioned on surviving the first month, the 1-year conditional survival for this group was 92% (90%-94%). Relative to the general population of the same age, their 1-year relative conditional survival probability was estimated at 99% (97%-101%). In other words, if patients with STEMI ≥76 years survive 1 month, their prognosis becomes the same as that of the general population. Furthermore, in the younger age categories, as well as in patients with NSTEMI and SAP, similar patterns were found albeit less pronounced. Altogether, these results demonstrate that relative conditional survival estimates may provide an important and meaningful addition when discussing prognosis with a patient. It should be noted that the incremental information conveyed by relative conditional survival estimates, as compared with cumulative survival probabilities, is most pronounced in groups where the survival probability is low and less so in those where survival is high (as witnessed in the youngest group of patients in our study for example). Our findings were supported by a regression model, where age, Our results suggest that accounting for the time already survived is useful for providing a comprehensive picture of patient prognosis, in particular for patients who are older and who have experienced a STEMI. In such patients, 1-year survival probability conditional on surviving the first month was 9% higher than cumulative survival probability as estimated from the start of follow-up. This finding complies with existing literature, showing that most events occur in the first month after PCI, making the first month the most crucial period. The 1-year survival probability was even higher for patients who survived the first year post-PCI. Because conditional survival can be calculated at every time point during follow-up, a patient's survival status can be used to repeatedly update prognosis. This enables dynamic modeling of prognosis, which provides a more accurate and comprehensive picture at any specific time point during follow-up. Further into the follow-up, the 1-year conditional survival probabilities appeared to decline, especially in the older age groups. A possible explanation for this decrease may be that these patients were aging and were therefore becoming more likely to die. Calculating relative survival enables incorporation of information on aging of patients because it relates their survival to the expected survival of individuals in the general population with the same age and sex. Accordingly, for every age group and indication studied here, the 1-year Figure 2 . One-year conditional survival estimates stratified by indication for percutaneous coronary intervention (PCI) and age. A, Oneyear conditional survival estimates. B, One-year relative conditional survival estimates. The lines in the graph indicate the 1-year survival probabilities conditional on having survived the period of time indicated on the x axis. The graph can also be interpreted-at having survived 4 years for example-as the probability of surviving 5 years, given the survival of the first 4 years. The subplots are zoomed in on the first 6 months after PCI. Error bars, 95% confidence intervals. NSTEMI indicates non-ST-segment-elevation myocardial infarction; SAP, stable angina pectoris; and STEMI, ST-segment-elevation myocardial infarction. Relative Conditional Survival After PCI relative conditional survival conditioned on the first month or any longer period during follow-up (up to 10 years) was ≥97%. This indicates that for patients undergoing PCI, and in particular those experiencing STEMI, survival probabilities become close to the survival of the general population after they survive the first month after the procedure.
In oncology research, relative and conditional survival are used to investigate at which moment after undergoing treatment a patient's prognosis becomes equal again to the prognosis of the general population. [7] [8] [9] In cardiovascular research however, these methods are used less often, and in particular, the combination of these 2 methods has not been examined in such a large consecutive cohort. Alabas et al 13 and Gale et al 12 studied the relative survival of a large cohort at 6 months post-myocardial infarction. They found 6-month relative survival rates of ≈96% for patients aged <65 years (STEMI and NSTEMI). In patients aged 65 to 80 years, 6-month relative survival was between 85% and 92% for patients with STEMI and between 83% and 89% for patients with NSTEMI, depending on the year of admission. Although this study reported relative survival only at 1 year and not 6 months, the survival rates we found were all higher than those described in the study by Alabas et al. 13 The difference was largest for patients with NSTEMI. These differences may possibly be explained by the difference in period of admission. Alabas et al 13 21 calculated interval-specific 1-year relative survival for a STEMI population aged >80 years until 3 years follow-up. Their findings coincide with our results from the eldest patients with STEMI, where no residual risk was found after patients survived the first month of follow-up.
Our study showed that combining conditional and relative survival results in different estimates of prognosis compared with those that are obtained by merely considering cumulative survival or conditional or relative survival separately. Patients may benefit from the information conveyed by these methods because they provide a more up-to-date picture of the patient's situation and also take into account the survival of the general population.
Strengths of our study include large cohort size, longterm follow-up, and inclusion of several indications for catheterization. However, limitations should also be mentioned. First, the α used in the adjusted expected survival to account for the large prevalence of the disease of interest in the general population is not known and had to be approximated. In this study, however the difference between the unadjusted and adjusted expected survival was on average extremely small (the median difference was <0.0001 percentage point [interquartile range=0-0.0003 percentage points]), indicating that a possible over-or underestimation for α does not have a large impact on the analysis. Furthermore, we were not able to account for age, indication for catheterization, and sex in the survival tables simultaneously. Even larger study size is required for such an analysis. The survival model, however, is capable of accounting for all variables together. The results from the regression model concurred with the stratified survival estimates. Finally, because this was a single-center study, external validation is warranted.
In conclusion, long-term survival prognosis for patients undergoing PCI for STEMI, NSTEMI, or SAP can be supplemented by estimates of conditional and relative conditional survival. Conditional survival probabilities incorporate information on the patient's survival up to a certain time point. Relative survival relates the patient's survival to the general population and may be particularly useful for older patients. In this study, the most prominent findings pertained to patients with STEMI aged 76 to 95 years. Their 1-year survival at the start of follow-up was 83%. Conditioned on surviving the first month, the 1-year conditional survival was 92%. Relative to the general population, it was 99%, meaning that once these patients survived the first month after PCI, their 1-year survival Parameter estimates are interpreted as relative excess risks estimates or excess hazard ratios. For example, the estimate of 6.98 for the interaction between STEMI and follow-up time indicates that there is a 7-fold increased excess risk of mortality (compared with the general population) for patients with STEMI in the first year after PCI compared with the remainder of the follow-up, adjusted for age and sex. The nonsignificant estimate of 1.22 for the patients with STEMI versus SAP after 1 year of follow-up indicates that after the first year of follow-up, there is no excess risk for the patients with STEMI compared with the patients with SAP. NSTEMI indicates non-ST-segment-elevation myocardial infarction; SAP, stable angina pectoris; and STEMI, ST-segment-elevation myocardial infarction.
probability was essentially the same as that of the general population. In sum, the information obtained from these 2 survival methods provides additional insights into prognosis and could therefore be helpful when communicating prognosis to patients.
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